Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review
European Child & Adolescent Psychiatry · 2025-01 · 34 (1) · 141-157
DOI: 10.1007/s00787-024-02458-y ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Child & Adolescent Psychiatry, online erschienen am 16.05.2024. Verfasst von Alisha M Bruton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland, OR, USA. BrutonA@ohsu.edu. Hauptthemen laut MEDLINE: Ketamine, Mood Disorders, Anxiety Disorders, Suicidal Ideation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCCIH NIH HHS, Oregon Health and Science University, Philanthropic funding.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Mood disorders, anxiety, and suicidality in youth are increasing and rapid-acting treatments are urgently needed. One potential is ketamine or its enantiomer esketamine, which was FDA approved in 2019 to treat major depressive disorder with suicidality in adults. This systematic review evaluated the evidence for the clinical use of ketamine to treat mood disorders, anxiety, and suicidality in youth. The PRISMA guidelines were used, and a protocol registered prospectively ( https://osf.io/9ucsg/ ). The literature search included Pubmed/MEDLINE, Ovid/MEDLINE, Scopus, CINAHL, PsychInfo, and Google Scholar. Trial registries and preprint servers were searched, and authors contacted for clarification. Studies reported on the clinical use of ketamine to treat anxiety, depression, bipolar disorder, or suicidality in youth ≤19 years old and assessed symptoms before and after ketamine use. Study screening and data extraction were conducted independently by 2-4 authors. Safety, tolerability, and efficacy data were collected. The Cochrane Risk of Bias guidelines assessed the quality of the evidence. Twenty-two published reports based on 16 studies were identified: 7 case studies, 6 observational studies, 3 randomized trials, and 6 secondary data analyses. Studies reported immediate improvements in depression, anxiety, and suicidality. Improvements were maintained for weeks-months following treatment. Ketamine was well-tolerated with the most common side effects being dizziness, nausea, and mild dissociation. Transient hemodynamic changes were reported, all of which resolved quickly and did not require medical intervention. Initial evidence suggests ketamine is safe and may be effective for mood disorders, anxiety, and suicidality in youth. Further randomized trials are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oregon Health & Science University, Portland, OR, USA. BrutonA@ohsu.edu.
- Oregon Health & Science University, Portland, OR, USA.
- University of Lethbridge, Lethbridge, Canada.
Förderung
- NCCIH NIH HHS
- Oregon Health and Science University
- Philanthropic funding
- National Center for Complementary and Integrative Health
- Oregon Health Authority
Zitieren
APA
Bruton, A. M., Wesemann, D. G., Machingo, T. A., Majak, G., Johnstone, J. M., & Marshall, R. D. (2025). Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review. European Child & Adolescent Psychiatry, 34(1), 141-157. https://doi.org/10.1007/s00787-024-02458-y
Vancouver
Bruton AM, Wesemann DG, Machingo TA, Majak G, Johnstone JM, Marshall RD. Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review. European Child & Adolescent Psychiatry. 2025;34(1):141-157. doi:10.1007/s00787-024-02458-y
BibTeX
@article{Bruton2025,
author = {Bruton, Alisha M and Wesemann, Dalton G and Machingo, Taryn A and Majak, Gop and Johnstone, Jeanette M and Marshall, Rebecca D},
title = {Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review},
journal = {European Child & Adolescent Psychiatry},
year = {2025},
volume = {34},
number = {1},
pages = {141--157},
doi = {10.1007/s00787-024-02458-y}
}
EUVIMED